Are Analysts Bullish Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) After Last Week?

Investors sentiment increased to 1.8 in Q3 2018. Its up 0.27, from 1.53 in 2018Q2. It improved, as 11 investors sold Vanda Pharmaceuticals Inc. shares while 35 reduced holdings. 36 funds opened positions while 47 raised stakes. 51.01 million shares or 7.09% more from 47.64 million shares in 2018Q2 were reported.
Texas Permanent School Fund holds 0.01% or 32,946 shares. Pnc Service Gp has invested 0.01% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Prudential Inc has invested 0.03% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Morgan Stanley invested in 520,349 shares. Hartford Management Co holds 0.01% or 10,539 shares. Dekabank Deutsche Girozentrale owns 10,600 shares or 0% of their US portfolio. Barclays Public Lc, a United Kingdom-based fund reported 65,232 shares. 66,111 are owned by Laurion Cap Lp. Arizona State Retirement Sys holds 0.03% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 130,000 shares. Prelude Cap Management Limited Liability Company owns 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) for 923 shares. American Interest Gru Inc Inc has invested 0% in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Qs Invsts Lc has invested 0.07% of its portfolio in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Geode Management Limited Liability has 0% invested in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA). Panagora Asset reported 430,093 shares. Numerixs Technology holds 0.01% or 2,035 shares in its portfolio.

Since January 2, 2019, it had 0 buys, and 4 sales for $751,326 activity. Birznieks Gunther sold 6,061 shares worth $159,810. $30,042 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was sold by Reverberi Gian Piero. Kelly James Patrick also sold $159,811 worth of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday, January 2.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Ratings Coverage

Among 6 analysts covering Vanda Pharmaceuticals (NASDAQ:VNDA), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Vanda Pharmaceuticals had 10 analyst reports since August 23, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, October 16 by Citigroup. Oppenheimer maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Friday, September 21 with “Outperform” rating. The company was maintained on Tuesday, December 11 by Stifel Nicolaus. The rating was downgraded by Oppenheimer to “Perform” on Tuesday, December 11. The firm earned “Market Outperform” rating on Thursday, December 6 by JMP Securities. The stock of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has “Overweight” rating given on Tuesday, December 4 by Cantor Fitzgerald. Citigroup maintained Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Friday, December 7 with “Buy” rating. Below is a list of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) latest ratings and price target changes.

11/12/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $36 New Target: $44 Maintain
11/12/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Perform New Target: $29 Downgrade
07/12/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $31 New Target: $47 Maintain
06/12/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $36 New Target: $52 Maintain
04/12/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight New Target: $43 Upgrade
08/11/2018 Broker: Jefferies Rating: Buy New Target: $26 Initiates Coverage On
16/10/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $27 New Target: $31 Maintain
21/09/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Outperform Old Target: $27 New Target: $29 Maintain
14/09/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $30 Initiates Coverage On
23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $26 Initiates Coverage On

The stock decreased 0.52% or $0.15 during the last trading session, reaching $28.69. About 20,297 shares traded. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 106.26% since January 14, 2018 and is uptrending. It has outperformed by 106.26% the S&P500.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company has market cap of $1.51 billion. The companyÂ’s marketed products include HETLIOZ , a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. It has a 112.95 P/E ratio. The Company’s clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

More notable recent Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) news were published by: Bizjournals.com which released: “Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer – Washington Business Journal” on May 04, 2017, also Nasdaq.com with their article: “Inovio (INO) to Receive Milestone Payment From AstraZeneca – Nasdaq” published on December 05, 2018, Nasdaq.com published: “The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance – Nasdaq” on December 13, 2018. More interesting news about Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) were released by: Benzinga.com and their article: “28 Stocks Moving In Wednesday’s Pre-Market Session – Benzinga” published on September 26, 2018 as well as Nasdaq.com‘s news article titled: “Health Care Sector Update for 12/03/2018: TSRO, GSK, VNDA, GBT, JNJ, PFE, ABT, MRK, AMGN – Nasdaq” with publication date: December 03, 2018.

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.